The NMPA of China has approved toripalimab plus axitinib for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic RCC.
A phase 2 trial showed that Trodelvy plus Keytruda had a high response rate with lasting responses, emphasizing “potential additive or synergistic effects,” an expert said.